Skip to main content

Table 5 Full group and subgroup analyses (based on the complete case approach)

From: Cost-effectiveness of acupuncture for irritable bowel syndrome: findings from an economic evaluation conducted alongside a pragmatic randomised controlled trial in primary care

 

Acupuncture Mean (SD) (n = 77)

Usual care Mean (SD) (n = 53)

Difference unadjusted (BCA 95% CI)

Difference adjusted* (BCA 95% CI)

 

Costs

  

Total costs at baseline (full group)

113 (256)

126 (138)

  

Mild

72 (146)

169 (138)

  

Moderate

134 (329)

119 (126)

  

Severe

95 (122)

130 (170)

  

Total costs during trial (full group)

869 (680)

650 (833)

218.50 (−55.17 to 492.18)

230.78 (−34.52 to 496.08)

Mild

900 (936)

404 (264)

496.46 (−244.24 to 1237.17

590.57 (−51.58 to 1232.72)

Moderate

876 (722)

698 (1014)

178.61 (−251.54 to 608.77)

164.59 (−229.41 to 558.60)

Severe

774 (403)

576 (355)

197.68 (−29.68 to 425.03)

231.87 (−11.68 to 475.42)

 

Outcomes

  

QALYs (full group)

0.7534 (0.1846)

0.7365 (0.1870)

0.0035 (−0.0389 to 0.0458)#

0.0033 ( −0.0398 to 0.0462)

Mild

0.7650 (0.2431)

0.8356 (0.1034)

−0.0406 (−0.2038 to 0.1227)

−0.0399 (−0.2053 to 0.1256)

Moderate

0.7822 (0.1720)

0.7752 (0.1541)

−0.0103 (−0.0586 to 0.0380)

−0.0107 (−0.0596 to 0.0382)

Severe

0.7049 (0.1885)

0.6683 (0.2363)

0.0310 (−0.0576 to 0.1197)

0.0309 (−0.0588 to 0.1206)

  1. Note: baseline SSS missing for 1 Acupuncture patient and 3 Usual care patients.
  2. #The difference in QALYs is always adjusted for baseline EQ-5D scores.
  3. *The difference in costs is adjusted for baseline costs.